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Abstract
Objective: To compare the efficacy of vaginal misopros-
tol versus dinoprostone for induction of labor (IOL) in
patients with preeclampsia according to the WHO
criteria.
Study design: Ninety-eight patients were retrospectively
analyzed. A total of 47 patients received 3 mg dinopros-
tone suppositories every 6 h (max. 6 mg/24 h) whereas
51 patients in the misoprostol group received either
50 mg misoprostol vaginally every 12 h, or 25 mg every
6 h (max. 100 mg/24 h). Primary outcomes were vaginal
delivery within 24 and 48 h, respectively.
Results: The probability of delivering within 48 h was
more than three-fold higher in the misoprostol than in the
dinoprostone group: odds ratio (OR)s3.48; 95% confi-
dence interval (CI) 1.24, 10.30, whereas no significant dif-
ference was observed within 24 h (Ps0.34). No
correlation was seen between a ripe cervix prior to IOL
and delivery within 24/48 h (Ps0.33 and Ps1.0, respec-
tively). More cesarean sections were performed in the
dinoprostone group due to failed IOL (Ps0.0009). No
significant differences in adverse maternal outcome were
observed between both study groups, whereas more
neonates (12 vs. 6) of the dinoprostone group were
admitted to the NICU (Ps0.068).
Conclusion: This study suggests that misoprostol may
have some advantages compared to dinoprostone,
including improved efficacy and lower cost of the drug,
even in cases of preeclampsia.
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Introduction
Preeclampsia complicates approximately 5% of all preg-
nancies and is associated with significant morbidity and
mortality for both the pregnant patient and her fetus w15x.
Furthermore, the only way to arrest disease progression
is to deliver the fetus and placenta. Therefore, induction
of labor (IOL) in case of mild or moderate preeclampsia
is often the method of choice, also intended to avoid
cesarean section associated complications. IOL has
become a routine procedure in obstetrical management,
especially in developed countries, currently affecting
more than 20% of all deliveries in the United States (US)
w8x. The success of IOL may not only be dependent on
the ripeness of the cervix, but also on the inducing agent.
In the case of an unripe cervix, the use of prostaglandins,
introduced in the 1960s for cervical ripening, is approved
as first-line treatment. Prostaglandin (PG) E2 is currently
the only regimen for cervical ripening that has been
approved in the US by the U.S. Food and Drug Admin-
istration (FDA), whereas misoprostol (PGE1), recom-
mended by the ACOG as an alternative agent for IOL in
women without a previous uterine scar, is considered to
be an off-label indication w1x. Advantages of PGE1
include high efficacy, low cost and easy storage condi-
tions. Misoprostol showed a higher efficacy than other
vaginal or intracervical prostaglandins for IOL in the case
of non-preeclamptic patients w7, 16x.
However, there exist only few trials that investigated
the effectiveness of both agents, specifically in the case
of preeclampsia w5, 9, 10, 12, 22x. Furthermore, induction
of labor often may be challenging in the case of pre-
eclampsia due to generally unfavorable Bishop scores,
lower gestational age and a high proportion of nulliparity
and intravenously applicated magnesium, which may
have a tocolytic effect w10x. In preeclampsia it is partic-
ularly important to aim for deliveries within 24–48 h, as
the condition has a tendency to worsen with time. In the
present study we aimed to determine the effectiveness
of vaginal misoprostol for labor induction in preeclampsia
as compared with dinoprostone in a single tertiary center.
Primary outcomes were vaginal delivery within 24 and
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48 h. Secondary outcome measures included the induc-
tion to delivery interval, maternal and fetal outcome,
mode of delivery and drug related side effects.
Methods
This retrospective study was conducted at one tertiary center. A
total of ninety-eight patients (51 in the misoprostol and 47 in the
dinoprostone groups) were identified from the database of the
Women’s University Hospital of Basel between the period of
January 1990–December 1996 (dinoprostone group) and Janu-
ary 1999–December 2002 (misoprostol group). In those two time
periods, dinoprostone and subsequently misoprostol represent-
ed the first line agent for IOL, taking the exclusion criteria into
account (e.g., hypersensibility to prostaglandins, previous cesa-
rean section in case of misoprostol). The inclusion criteria con-
sisted of induced patients with preeclampsia, according to the
WHO criteria whypertension )140/90 mm Hg, increase of the
systolic or diastolic blood pressure)30 mm Hg and 15 mm Hg,
respectively, on two occasions at least 6 h apart, in combination
with proteinuria ()300 mg/24 h)x, singleton fetuses in vertex
presentation, intact amniotic membranes and absence of active
labor. Exclusion criteria were: previous uterine surgery, placenta
previa, fetal anomaly, known allergy to prostaglandins, maternal
age -18 years and pathologic non-stress cardiotocogram prior
to induction. The patients received either misoprostol (PG E1) in
a dose regimen of 25 mg vaginally every 6 h, or 50 mg vaginally
every 12 h. The maximum dose for all women was 100 mg/24 h.
The patients in the dinoprostone group received 3 mg dinopros-
tone suppositories with a 6-h time interval (maximum of 6 mg/
24 h). External electronic fetal monitoring was performed 30 min
before and 120 min after each medication was administered. If
there were no contractions, 6 or 12 h after the first dose,
dependent on the dose regimen, each patient was digitally re-
assessed. When the Bishop score was F8, a second dose of
dinoprostone or misoprostol was administered, according to the
guidelines. The procedure was repeated the following day. If pro-
gress towards delivery did not occur after 48 h or if the under-
lying disease had progressed, the patient was re-evaluated for
further management. No further dose of either medication was
given if there were uterine contractions, if the membranes rup-
tured spontaneously or if there were fetal heart rate abnormali-
ties. The subsequent management of labor was identical for
both groups. In case of failure of cervical dilatation (-1 cm/h)
or no progress during the active first and second stage of labor,
intravenous oxytocin by infusion pump, at least six hours apart
from the last PG application, was initiated with increasing doses
from 1.25 up to 20 mU/min. Surveillance of fetal heart rate (FHR)
and uterine activity were monitored in all patients. FHR patterns
were analyzed according to the RCOG guideline w2x. In the case
of severe preeclampsia (onset prior to 34 weeks, indicated by
proteinuria )5 g/24 h, hypertension)160/110 mm Hg), or clin-
ical signs (visual disturbances, hyperreflexia, severe headache),
an anticonvulsive prophylaxis with intravenous magnesium sul-
fate was initiated by a 4 g bolus over 20 min, followed by a
continuous therapy of 2 g/h, according to quantitative measure-
ments, until 48 h postpartum. All data were collected from the
hospital records. The assessment of the cardiotocograms for
uterine contraction abnormalities and abnormal fetal heart rate
pattern was performed during labor and recorded in the patient’s
chart. The endpoint chosen to evaluate the effectiveness of
misoprostol and dinoprostone were the achievement of a vaginal
delivery within 24 and 48 h, respectively. The sample size was
calculated using the power analysis from a previous study of
patients without preeclampsia to detect a 35% difference in the
number of patients delivered within 24 h w16x. Thus, 48 patients
in each group were required for the study to have a power of
80% at a type I error level of 0.05.
Statistical analysis
To compare approximate normally distributed data in the groups,
Student’s t-test was used and mean with standard deviationwas
calculated. Data were logarithmically transformed if necessary.
Mann-Whitney U-test was used for ordinal data and median
with range was tabulated. To describe associations in cross
tabulations, Fisher exact test was performed and odds ratios
with corresponding 95% confidence intervals were reported. A
P-value -0.05 was considered significant. As this was an
exploratory study we did not adjust the P-values for multiple
comparisons. All analyses were performed using SPSS (SPSS
Inc., Chicago, USA) 11.5.1.
Results
Both groups were comparable in terms of demographic
and obstetric data, such as maternal age, gravidity, par-
ity, gestational age and birth weight (Tables 1 and 2). The
Bishop scores collected prior to IOL were not statistically
different in both groups (Ps0.33; Table 1). No correlation
was seen between a ripe cervix (Bishop score )6) and
delivery within 24 h between both groups wodds ratio
(OR)s 0.33; (95% confidence interval (CI) 0.026–3.18)x,
or within 48 h wORs0.85; (95% CI 0.07–7.96), respec-
tivelyx. A total of 78% (40/51) in the misoprostol group
delivered spontaneously or by vaginal operative delivery
as compared to 64% (30/47) in the dinoprostone group
(Ps0.123). The rate of cesarean section (CS) did not dif-
fer between the groups (Ps0.12); however, CS was
required due to failure of induction in none (misoprostol)
versus 11 patients in the dinoprostone group
(Ps0.0009).
The type of PG administered for ripening had no sig-
nificant influence on the mean induction to delivery time
interval (Ps0.2; Table 2). However, a statisticaly signifi-
cant difference in the frequency of delivery within 48 h
was observed: 30 patients in the misoprostol group ver-
sus 13 in the dinoprosone group delivered vaginally with-
in 48 h (Ps0.01). In contrast, the rate of vaginal deliveries
within 24 h was not statistically different between both
groups (19 patients in the misoprostol group, nine
patients in the dinoprostone group, Ps0.15). The prob-
ability of a vaginal delivery within 48 h was more than
three-fold higher with misoprostol than with dinoprostone
(ORs3.48; 95% CI: 1.23–10.30), whereas no significant
difference was seen in vaginal deliveries within 24 h
between both groups (ORs2.09; 95% CI: 0.72–6.38).
The dose of oxytocin administered during labor did not
differ statistically between both groups (Ps0.34). Fur-
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Table 1 Population demographic and obstetric characteristics of the two groups.
Variable Drugs P
Misoprostol Dinoprostone
ns51 ns47
Maternal age (years) (SD) 29.31 (5.4) 28.49 (4.8) 0.43*
Gestational age at delivery (weeks) 39.11 38.34 0.49**
(range) (SD) (34–42) (2.8) (32–42) (2.1)
Gravidity (SD) 1.55 (1.0) 1.94 (1.5) 0.14**
Nulliparity (n (%)) 38 (74.5) 34 (72.3) 0.82***
Bishop score (SD) 2.93 (1.4) 3.27 (1.8) 0.34*
Magnesium sulfate intravenously (%) 8 (15.7) 10 (21.2) 0.60***
Vaginal delivery (n (%)) 40 (78.4) 30 (63.8) 0.12***
Spontaneous/vaginal operative
Cesarean section due to failure of 0 9 0.0009***
induction of labor (n)
Mean values; *Welch two sample t-test; **Exact Wilcoxon rank sum test; ***Fisher exact test; SD: standard deviation.
Table 2 Maternal and fetal outcome parameters of both groups.
Variable Drugs P
Misoprostol Dinoprostone
ns51 ns47
Birth weight (g), mean 3215 3019 0.11*
Median (SD) 3270 (631) 3215 (779)
Blood loss (mL), mean 448 470 0.72*
Median (SD) 400 (200) 400 (157)
Induction to delivery interval (h) mean 32.3 50.3 0.2*
Median (SD) 26.0 (20.0) 35.8 (39.4)
Number of drug applications (SD) 2.41 (1.7) 2.89 (2.1) 0.29**
APGAR score -7 at 5 min (n) 1 6 0.05***
Admission to NICU (n) 6 12 0.068***
Meconium stained amniotic fluid (n) 8 10 0.60***
*Welch two sample t-test, **Exact Wilcoxon rank sum test, ***Fisher exact test.
thermore, no prolongation towards longer vaginal birth
periods was seen in cases where magnesium sulfate was
intravenously administered (Ps0.56).
No significant differences in adverse maternal outcome
were observed between both study groups. In contrast,
some fetal outcome variables differed between both
groups: during labor, one case of hyperstimulation syn-
drome was observed in the dinoprostone group. Lower
Apgar scores (-7) at five minutes were observed in the
dinoprostone group versus the misoprostol group
(P-0.05; Table 2). Similarly, more neonates of the dino-
prostone group (ns12) were admitted to the NICU, com-
pared to the misoprostol group (ns6, Ps0.068). During
labor, no difference was observed in the frequency of
meconium stained amniotic fluid (Ps0.6).
Discussion
This study assessed the effectiveness of vaginally admin-
istered misoprostol versus dinoprostone in pregnant
women with preeclampsia and mostly unfavorable cervix
w9x. The data show an association with the applied PG
and delivery within 48 h, supporting the results of our and
other previous studies in the case of non-preeclamptic
patients w3, 6, 16x. However, we did not see an associ-
ation between a ripe cervix (Bishop score )6) and deliv-
ery intervals in both groups, in contrast to other studies
in healthy pregnant women showing high predictive val-
ues of high Bishop scores w18, 20x.
Only few trials have assessed the potential role of
misoprostol and dinoprostone in preeclampsia w9, 12x.
Our data are in accordance with those demonstrating a
higher effectiveness of misoprostol than dinoprostone in
IOL in patients with preeclampsia. The literature referring
to labor induction provides some evidence that the use
of misoprostol tends to be more effective than dinopros-
tone for cervical ripening, especially in patients with an
unfavorable cervix. However, their use is frequently asso-
ciated with uterine hyperstimulation, meconium stained
amniotic fluid and fetal heart tracing abnormalities w19x.
Cardiotocographic abnormalities occurred frequently
after the use of misoprostol w11x. In our study we did not
note these findings, probably due to our dose regimens,
except for one case of hyperstimulation syndrome in the
dinoprostone group. Various doses of misoprostol have
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been explored for IOL. Misoprostol at doses of 25 mg
seems to be as effective as 50 mg in selected patients
w13, 18x.
Regarding the application route of misoprostol, one
study compared 50 mg of misoprostol orally and vagi-
nally four hourly to a maximum of five doses w14x. The
authors demonstrated that vaginal misoprostol has a fas-
ter action than the oral route in equivalent doses. How-
ever, more hyperstimulations and higher intervention
rates for fetal distress were seen in the vaginal group,
using the above mentioned dose regimen. Therefore,
more studies are needed to assess the risk-benefit ratio
for both application routes. Some data suggest that pre-
eclampsia is associated with longer induction to delivery
intervals w5x. Griffiths et al. reported a median value of
the induction to delivery interval of 17.48 h versus 12.7 h
in the control group, using 1 or 2 mg of prostaglandin
E2, dependening on the Bishop score. Compared to the
study of Griffiths and co-workers, the values of the
induction to delivery intervals in this study are 1.9-fold
higher in the misoprostol group, and 2.9-fold higher than
in the prostaglandin E2 group, respectively. A recent
study concluded that preeclampsia is not an independ-
ent risk factor for failed inductions after administration of
PGE2, in contrast to maternal weight, unfavorable cervix,
or magnesium sulfate w10x. In the case of intravenous
magnesium, we could not confirm a trend towards longer
time to delivery, in agreement with other studies that did
not show a negative effect of intravenous magnesium
sulfate therapy on labor duration w17, 21x. In our study,
vaginal delivery was achieved in 78% of the misoprostol
group, confirming findings from previous studies using
misoprostol in case of preeclampsia w4, 9, 12x. The lower
rate of 64% in the dinoprostone group may be explained
by a higher proportion of failed inductions. Eleven of a
total of 17 cesarean sections in this group were per-
formed due to failed induction. Furthermore, more neo-
nates from the dinoprostone group were admitted to the
NICU, either due to meconium aspiration (three of 12
cases), pneumonia (one case), hyperbilirubinemia (one
case), preterm delivery (three cases), and delayed adap-
tation (four cases), compared to three neonates in the
misoprostol group with slow adaptation, two with pre-
term delivery and one with a transient infant distress syn-
drome. Whereas dinoprostone is approved in most
countries as vaginal suppositories or vaginal gel for IOL,
misoprostol is not. However, numerous randomized stud-
ies exist on the use of misoprostol for induction of labor,
and large specialist societies such as the ACOG rec-
ommend its use w1x. Nevertheless, the clinician has to
take into account the medical and legal implications of
off-label use of misoprostol in pregnant women.
In conclusion, our data indicate that vaginal misopros-
tol seems to be superior compared to prostaglandin E2
for cervical ripening and IOL in patients with preeclamp-
sia, due to improved efficacy, a reduced need for CS due
to failed IOL, a favorable side-effect spectrum and lower
costs of the drug.
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